Drug Profile
Bexlosteride
Alternative Names: LY 300502Latest Information Update: 09 Feb 2000
Price :
$50
*
At a glance
- Originator Eli Lilly and Company
- Class Antineoplastics; Small molecules
- Mechanism of Action Cholestenone 5-alpha reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 09 Feb 2000 LY 300502 is now called bexlosteride (USAN)
- 01 Apr 1999 No-Development-Reported for Prostate cancer in USA (PO)
- 31 Oct 1997 Phase-II clinical trials for Prostate cancer in USA (PO)